

ASX ANNOUNCEMENT

Appointment of Dr Peter French to Benitec Board

SYDNEY Australia, 26 August 2013: RNAi-based therapeutics company Benitec Biopharma Limited (ASX:BLT) is pleased to announce the appointment of the Company's Chief Executive Officer (CEO), Dr Peter French, to the role of Managing Director.

Dr French joined Benitec in 2009 as its Chief Scientific Officer, and was subsequently appointed to the role of CEO in June 2010. During his time as CEO, Dr French was responsible for driving Benitec's clinical development strategy, with lead programs in Hepatitis C and lung cancer now preparing to enter clinical trials.

Benitec's Chairman, Mr Peter Francis, welcomed Dr French's appointment to the Board saying "Peter's achievements as CEO in building the Company's portfolio of programs and directing its emergence as a clinical stage company make it highly appropriate that he join the Board and the Directors are delighted with this outcome."

For more information please contact: Greg West | Company Secretary
Phone: +61 (02) 9555 6986 pfrench@benitec.com | www.benitec.com

About Benitec Biopharma Limited: Benitec Biopharma Limited is an ASX-listed biotechnology company (ASX Code: BLT) based in Sydney, Australia. The company has a pipeline of in-house and partnered therapeutic programs based on its patented gene-silencing technology, ddRNAi. Benitec is developing treatments for chronic and life-threatening human conditions such as hepatitis C, hepatitis B, wet age-related macular degeneration, cancer-associated pain, drug resistant lung cancer and oculopharyngeal muscular dystrophy based on this technology. In addition, Benitec has licensed ddRNAi technology to other biopharmaceutical companies who are progressing their programs towards the clinic for applications including HIV/AIDS, retinitis pigmentosa and Huntington's disease. For more information on Benitec refer to the Company's website at www.benitec.com.